Rick, Genome Therapeutics....missing asset ?
This is only listed in the "Asset Purchase Agreement" details. Can't find reference to this in any other "retained asset" paragraphs. Is this worth anything ? A 10 year collaboration !
Genome Therapeutics listed this in their 10K 1998 but quiet in 10K 1999.
Cadus 10Q JUNE 30TH
ASSET PURCHASE AGREEMENT
......
1.2 Excluded Assets.
(h) Functional Genomics Program. All of Seller's rights in the
Functional Genomics Program;
===========
"Functional Genomics Program" means all rights related to the
activities conducted by Seller in collaboration with Genome Therapeutics
Corporation, including, but not limited to, the putative G protein-coupled
receptors identified (in whole or in part) within the collaboration and the
laboratory and bioinformatics technology owned or licensed by Seller to perform
such identification. The Functional Genomics Program explicitly includes all the
proprietary software created by Seller in Java and Perl and the contents of any
proprietary collection of information that the software accesses, except the
information (and programs designed to access such information) related to
Seller's Compounds or the results of screening Seller's Compounds. The
Functional Genomics Program further includes all the intellectual property owned
or licensed by Seller related to methods and compositions used to identify
surrogate or natural ligands to molecular targets, where the natural ligand to
such target is unknown.
=============
On July 25, 1998, the Company entered into a collaboration agreement with Genome Therapeutics Corporation, which has bioinformatics technologies and know-how that it uses to identify and sequence orphan G Protein-coupled receptors. The objective of the collaboration is to identify and isolate a large number of full length human orphan G Protein-coupled receptors and otherbiological targets and to enter into collaboration agreements, for the benefit of both the Company and Genome Therapeutics Corporation, with third party pharmaceutical companies to discover, develop and commercialize products thatact on such orphan G Protein-coupled receptors and other biological targets. The collaboration agreement has term of ten (10) years, but either party mayterminate it at any time on or after July 25, 1999 upon ninety (90) days priorwritten notice to the other party. Each of the Company and Genome Therapeutics Corporation bears its own expenses of engaging in the collaboration and shares in the research funding, equity investments, license fees, milestone payments and royalties that may be received from third party pharmaceutical companies that enter into collaboration agreements with the Company and/or Genome that enter into collaboration agreements with the Company and/or Genome Therapeutics Corporation with respect to the G Protein-coupled receptors and other biological targets identified and isolated pursuant to the collaboration between the Company and Genome Therapeutics Corporation
Dave |
